Pharmacology of peripheral opioid receptors

Current Opinion in Anaesthesiology

Volumn 24, Issue 4, 2011, Pages 408-413

  Rachinger Adam, Banafscheh ^a   Conzen, Peter ^a   Azad, Shahnaz C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Bowel dysfunction; cardioprotection; nociception; peripheral opioid receptors; pruritus; wound healing

Indexed keywords

17 METHYLNALOXONE; 17 METHYLNALTREXONE; ALVIMOPAN; CELECOXIB; FENTANYL; HYDROMORPHONE; MORPHINE; OPIATE; OPIATE RECEPTOR;

ABDOMINAL PAIN; ANALGESIA; ANGIOGENESIS; BLOOD BRAIN BARRIER; CONSTIPATION; FLATULENCE; HEART INFARCTION PREVENTION; HEART PROTECTION; HUMAN; ILEUS; INTESTINAL SPASM; LOW DRUG DOSE; NAUSEA; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; PRURITUS; REVIEW; SPINAL GANGLION; WOUND HEALING;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; CONSTIPATION; HUMANS; PAIN PERCEPTION; PRURITUS; PYRAZOLES; RECEPTORS, OPIOID; SULFONAMIDES; WOUND HEALING;

EID: 79960700559     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0b013e32834873e5     Document Type: Review

References (65)

1. Kieffer BL, Evans CJ. Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology 2009; 56 (Suppl 1):205-212.
2. Chen JJ, Dymshitz J, Vasko MR. Regulation of opioid receptors in rat sensory neurons in culture. Mol Pharmacol 1997; 51:666-673. (Pubitemid 27172995)
3. Ferreira SH, Nakamura M. II - Prostaglandin hyperalgesia: the peripheral analgesic activity of morphine, enkephalins and opioid antagonists. Prostaglandins 1979; 18:191-200. (Pubitemid 10226024)
4. Stein C, Millan MJ, Shippenberg TS, et al. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 1989; 248:1269-1275. (Pubitemid 19100783)
5. Zollner C, Shaqura MA, Bopaiah CP, et al. Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol Pharmacol 2003; 64:202-210. (Pubitemid 36909983)
6. Jeanjean AP, Moussaoui SM, Maloteaux JM, Laduron PM. Interleukin-1 beta induces long-term increase of axonally transported opiate receptors and substance P. Neuroscience 1995; 68:151-157.
7. Mousa SA, Cheppudira BP, Shaqura M, et al. Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain. Brain 2007; 130:502-513. (Pubitemid 46181103)
8. Berg KA, Patwardhan AM, Sanchez TA, et al. Rapid modulation of microopioid receptor signaling in primary sensory neurons. J Pharmacol Exp Ther 2007; 321:839-847. (Pubitemid 46762685)
9. Schafer M, Carter L, Stein C. Interleukin 1 beta and corticotropin- releasing factor inhibit pain by releasing opioids from immune cells in inflamed tissue. Proc Natl Acad Sci U S A 1994; 91:4219-4223.
10. Binder W, Mousa SA, Sitte N, et al. Sympathetic activation triggers endogenous opioid release and analgesia within peripheral inflamed tissue. Eur J Neurosci 2004; 20:92-100. (Pubitemid 38932130)
11. Rittner HL, Labuz D, Schaefer M, et al. Pain control by CXCR2 ligands through Ca2-regulated release of opioid peptides from polymorphonuclear cells. FASEB J 2006; 20:2627-2629.
12. Heurich M, Mousa SA, LenznerM, et al. Influence of pain treatment by epidural fentanyl and bupivacaine on homing of opioid-containing leukocytes to surgical wounds. Brain Behav Immun 2007; 21:544-552. (Pubitemid 46830962)
13. Labuz D, Mousa SA, Schafer M, et al. Relative contribution of peripheral versus central opioid receptors to antinociception. Brain Res 2007; 1160:30-38. (Pubitemid 47061436)
14. Mangel AW, Bornstein JD, Hamm LR, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28:239-249. (Pubitemid 351861967)
15. Wallace MS, Moulin D, Clark AJ, et al. A Phase II, multicenter, randomized, double-blind, placebo-controlled crossover study of CJC-1008 - a longacting, parenteral opioid analgesic - in the treatment of postherpetic neuralgia. J Opioid Manag 2006; 2:167-173.
16. Azad SC, Beyer A, Romer AW, et al. Continuous axillary brachial plexus analgesia with low dose morphine in patients with complex regional pain syndromes. Eur J Anaesthesiol 2000; 17:185-188. (Pubitemid 30237294)
17. Antonijevic I, Mousa SA, Schafer M, Stein C. Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci 1995; 15:165-172.
18. Schramm CL, Honda CN. Co-administration of delta- and mu-opioid receptor agonists promotes peripheral opioid receptor function. Pain 2010; 151:763-770.
19. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage 2007; 34:547-565. (Pubitemid 350001379)
20. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic noncancer pain: systematic review of efficacy and safety. Pain 2004; 112:372-380. (Pubitemid 39550738)
21. Holzer P. Opioid antagonists for prevention and treatment of opioid-induced gastrointestinal effects. Curr Opin Anaesthesiol 2010; 23:616-622.
22. Reimer K, Hopp M, Zenz M, et al. Meeting the challenges of opioid-induced constipation in chronic pain management: a novel approach. Pharmacology 2009; 83:10-17.
23. Gray AC, White PJ, Coupar IM. Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum. Br J Pharmacol 2005; 144:687-694. (Pubitemid 40445617)
24. Van Hoogmoed LM, Boscan PL. In vitro evaluation of the effect of the opioid antagonist N-methylnaltrexone on motility of the equine jejunum and pelvic flexure. Equine Vet J 2005; 37:325-328. (Pubitemid 40977427)
25. Slatkin N, Thomas J, Lipman AG, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol 2009; 7:39-46.
26. Thomas J, Karver S, Cooney GA, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358:2332-2343. (Pubitemid 351749157)
27. European Medicines Agency. Relistor. (methylnaltrexone bromide solution) EU prescribing information [online]. PDFs/EPAR/relistor/emea-combined-h870en. pdf. 2011. [Accessed 13April 2010]
28. Wong BS, Rao AS, Camilleri M, et al. The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health. Aliment Pharmacol Ther 2010; 32:884-893.
29. Becker G, Blum HE. Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 2009; 373:1198-1206.
30. Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting muopioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic noncancer pain. Pain 2008; 137:428-440.
31. Viscusi ER, Goldstein S, Witkowski T, et al. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc 2006; 20:64-70. (Pubitemid 43097035)
32. Ludwig K, Viscusi ER, Wolff BG, et al. Alvimopan for the management of postoperative ileus after bowel resection: characterization of clinical benefit by pooled responder analysis. World J Surg 2010; 34:2185-2190.
33. US Food and Drug Administration. FDA approves Entereg to help restore bowel function following surgery. 2008/ucml16899.htm. 2011. [Accessed 21 May 2010]
34. Schmelz M, Schmidt R, Bickel A, et al. Specific C-receptors for itch in human skin. J Neurosci 1997; 17:8003-8008. (Pubitemid 27426235)
35. Bonnet MP, Mignon A, Mazoit JX, et al. Analgesic efficacy and adverse effects of epidural morphine compared to parenteral opioids after elective caesarean section: a systematic review. Eur J Pain 2010; 14:894-899.
36. Reich A, Stander S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol 2009; 89:236-244.
37. Kuraishi Y, Yamaguchi T, Miyamoto T. Itch-scratch responses induced by opioids through central mu opioid receptors in mice. J Biomed Sci 2000; 7:248-252. (Pubitemid 30307744)
38. Thomas DA, Williams GM, Iwata K, et al. The medullary dorsal horn. A site of action of morphine in producing facial scratching in monkeys. Anesthesiology 1993; 79:548-554. (Pubitemid 23263700)
39. Yamamoto A, Sugimoto Y. Involvement of peripheral mu opioid receptors in scratching behavior in mice. Eur J Pharmacol 2010; 649:336-341.
40. Blunk JA, Schmelz M, Zeck S, et al. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg 2004; 98:364-370, table. (Pubitemid 38129381)
41. Bigliardi-Qi M, Sumanovski LT, Buchner S, et al. Mu-opiate receptor and betaendorphin expression in nerve endings and keratinocytes in human skin. Dermatology 2004; 209:183-189. (Pubitemid 39370325)
42. Lee CH, Chuang HY, Shih CC, et al. Transepidermal water loss, serum IgE and beta-endorphin as important and independent biological markers for development of itch intensity in atopic dermatitis. Br J Dermatol 2006; 154:1100-1107.
43. Clark RAF, editor. Wound repair: overview and general considerations. New York: Plenum Press; 1996. pp. 3-50.
44. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-674. (Pubitemid 27193480)
45. Bigliardi-Qi M, Gaveriaux-Ruff C, Zhou H, et al. Deletion of delta-opioid receptor in mice alters skin differentiation and delays wound healing. Differentiation 2006; 74:174-185.
46. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K. Opioids heal ischemic wounds in the rat. Wound Repair Regen 2005; 13:165-174. (Pubitemid 40489866)
47. Chen C, Farooqui M, Gupta K. Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells. Curr Neurovasc Res 2006; 3:171-180. (Pubitemid 44198470)
48. Romero A, Planas E, Poveda R, et al. Antiexudative effects of opioid receptor agonists in a rat model of carrageenan-induced acute inflammation of the paw. Eur J Pharmacol 2005; 511:207-217. (Pubitemid 40424569)
49. Rook JM, Hasan W, McCarson KE. Morphine-induced early delays in wound closure: involvement of sensory neuropeptides and modification of neurokinin receptor expression. Biochem Pharmacol 2009; 77:1747-1755.
50. RookJM,HasanW,McCarsonKE.Temporal effects oftopicalmorphineapplication on cutaneous wound healing. Anesthesiology 2008; 109:130-136.
51. Rook JM, McCarson KE. Delay of cutaneous wound closure by morphine via local blockade of peripheral tachykinin release. Biochem Pharmacol 2007; 74:752-757. (Pubitemid 47090181)
52. Krumins SA, Faden AI, Feuerstein G. Opiate binding in rat hearts: modulation of binding after hemorrhagic shock. Biochem Biophys Res Commun 1985; 127:120-128. (Pubitemid 15146940)
53. Schultz JE, Gross GJ. Opioids and cardioprotection. Pharmacol Ther 2001; 89:123-137. (Pubitemid 32333036)
54. Schultz JJ, Hsu AK, Gross GJ. Ischemic preconditioning is mediated by a peripheral opioid receptor mechanism in the intact rat heart. J Mol Cell Cardiol 1997; 29:1355-1362.
55. Wong GT, Ling LJ, Irwin MG. Activation of central opioid receptors induces cardioprotection against ischemia-reperfusion injury. Anesth Analg 2010; 111:24-28.
56. Maslov LN, Lishmanov YB, Oeltgen PR, et al. Comparative analysis of the cardioprotective properties of opioid receptor agonists in a rat model of myocardial infarction. Acad Emerg Med 2010; 17:1239-1246.
57. Schultz JE, Hsu AK, Gross GJ. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. Circulation 1998; 97:1282-1289. (Pubitemid 28169181)
58. Penning TD, Talley JJ, BertenshawSR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40:1347-1365. (Pubitemid 27198082)
59. Burian M, Geisslinger G. COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites. Pharmacol Ther 2005; 107:139-154. (Pubitemid 40910038)
60. Franca DS, Ferreira-Alves DL, Duarte ID, et al. Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan. Neuropharmacology 2006; 51:37-43. (Pubitemid 44192398)
61. Francischi JN, Chaves CT, Moura AC, et al. Selective inhibitors of cyclooxygenase- 2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol 2002; 137:837-844. (Pubitemid 35407490)
62. Rezende RM, Dos Reis WG, Duarte ID, et al. The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids. Pain 2009; 142:94-100.
63. Rezende RM, Paiva-Lima P, Dos Reis WG, et al. Celecoxib induces tolerance in a model of peripheral inflammatory pain in rats. Neuropharmacology 2010; 59:551-557.
64. Rezende RM, Franca DS, Menezes GB, et al. Different mechanisms underlie the analgesic actions of paracetamol and dipyrone in a rat model of inflammatory pain. Br J Pharmacol 2008; 153:760-768. (Pubitemid 351271767)
65. Correa JD, Paiva-Lima P, Rezende RM, et al. Peripheral mu-, kappa- and deltaopioid receptors mediate the hypoalgesic effect of celecoxib in a rat model of thermal hyperalgesia. Life Sci 2010; 86:951-956.